Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IP vs. Know-How: in RNAi, the Battle Is Joined

This article was originally published in Start Up

Executive Summary

Which is better: patents on the fundamental science for creating a new class of drugs--or the know-how for making drugs based on the idea? In one of the few bright areas of discovery-based biotech, RNA interference (RNAi), the battle between the two philosophical positions has been joined as an investor group has beaten Alnylam, the IP leader in RNAi, to the control of Ribozyme Pharmaceutical's RNA chemistry know-how.
Advertisement

Related Content

Early Movers in RNAi
In RNAi, Technology Proliferates Beyond the Big Two
In RNAi, Technology Proliferates Beyond the Big Two
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy
Novartis Opens Door to Broad Dealmaking in RNAi
RNAi-Based Drug Development
RNAi Firms Unite Rather than Fight
RNAi Revs Up
RNAi Revs Up

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel